A Japanese survey-based study conducted in the era of the COVID-19 pandemic—data were collected in October 2021—found that patients with psoriasis reported a preference for biologic therapies with a less frequent administration route/visit schedule and those that carried a lower risk of serious infections. These preferences represent a shift from previous surveys carried out in this patient population, in which drug efficacy was reported to be of the utmost importance. The results of these surveys of about 450 patients with psoriasis were published by Tada et al in The Journal of Dermatology. The relative importance of biologic characteristics reported by the respondents was highest for administration route and visits (24.21%), followed by risk of serious infections requiring hospitalization (23.10%), efficacy at 1 year (16.63%), incidence of injection site reactions (14.43%), and copayment (14.22%). The study authors noted that the shift in relative importance responses may have been influenced by the COVID-19 pandemic.
May 24, 2023